Related Experiment Videos
Abstract:
Acute diarrheal disease may be due to viral, bacterial, or protozoal enteropathogens. In our current state of knowledge and medical practice, specific antiviral agents are not used in the treatment of known or presumed viral diarrhea. In contrast, for a number of the bacterial and protozoal diarrheal infections, therapy with certain antimicrobial agents can significantly ameliorate the severity and duration of illness and curtail the excretion of the pathogen. A recurring theme encountered in reviewing information on the therapy for diarrheal infections is that demonstration of the susceptibility in vitro of a bacterial pathogen to a particular antibiotic by no means assures clinical success. Many antibiotics that show potent activity in vitro have little or no efficacy in vivo. Controlled clinical trials are necessary to assess the clinical and bacteriologic efficacy of an antibiotic in diarrheal infections.
Insights
Antimicrobial therapy can effectively treat bacterial and protozoal diarrhea, but in vitro antibiotic susceptibility does not guarantee clinical success. Controlled trials are essential for evaluating antibiotic efficacy in diarrheal infections.
Area of Science:
- Infectious Diseases
- Microbiology
- Clinical Pharmacology
Background:
- Acute diarrhea stems from viral, bacterial, or protozoal pathogens.
- Antiviral agents are not standard for viral diarrhea treatment.
- Antimicrobials can treat bacterial and protozoal diarrhea, reducing illness severity and pathogen shedding.
Purpose of the Study:
- To review the efficacy of antimicrobial agents in treating diarrheal infections.
- To highlight the discrepancy between in vitro antibiotic activity and in vivo clinical success.
- To emphasize the necessity of controlled clinical trials for validating antibiotic treatments for diarrhea.
Main Methods:
- Review of existing literature on diarrheal infection therapies.
- Analysis of the relationship between in vitro antibiotic susceptibility and clinical outcomes.
- Identification of the need for controlled clinical trials.
Main Results:
- In vitro antibiotic effectiveness does not reliably predict in vivo efficacy for bacterial pathogens.
- Many antibiotics potent in vitro show limited or no clinical benefit in vivo.
- Clinical trials are crucial for assessing real-world antibiotic performance.
Conclusions:
- Antimicrobial therapy is valuable for bacterial and protozoal diarrhea but requires careful evaluation.
- In vitro data alone is insufficient for selecting effective antibiotic treatments for diarrhea.
- Controlled clinical trials are indispensable for confirming the efficacy of antibiotics in managing diarrheal diseases.